Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

OCTOPUS: An Observational, Non-interventional, Non-comparative, Retrospective, Multicentre Study in Patients With Advanced Renal Cell Carcinoma (aRCC) Who Initiated Cabozantinib in 2nd Line Under Real-life Setting in France.

NCT05444933 is registered in ClinicalTrials.gov with Ipsen as lead sponsor.

NCT NCT05444933
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05444933 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
OCTOPUS: An Observational, Non-interventional, Non-comparative, Retrospective, Multicentre Study in Patients With Advanced Renal Cell Carcinoma (aRCC) Who Initiated Cabozantinib in 2nd Line Under Real-life Setting in France.
Lead sponsor
Ipsen
Phase
Observational
Overall status
Completed
Start date
September 16, 2022
Completion date
May 12, 2023
Enrollment
252 (actual)
Sites
28

Conditions

As the registry lists them; a condition with its own page is linked.

advanced renal cell carcinoma